Back to Search
Start Over
Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 1996 May; Vol. 21 (5-6), pp. 429-35. - Publication Year :
- 1996
-
Abstract
- Since 1988 we have treated a first group of 14 patients with recombinant interleukin-2 (rIL-2), which was previously published, and 6 other consecutive patients affected by refractory or relapsed acute myelogenous leukemia (AML) with >5% and < or = 30% bone marrow blasts, but not suitable for further chemotherapy. The rIL-2 schedule consisted of four 5-day high-dose cycles administered by continuous infusion with a 72-hour rest period between each cycle. Patients who achieved a response received a lower dose of subcutaneous rIL-2 maintenance treatment administered for 5 days every month. Following high-dose rIL-2, 11/20 patients (55%) obtained a complete remission (CR). Six remain in persistent CR after a median follow-up time of 50 months (9, 33, 49, 51, 52, 87 months, respectively); the length of remission is the longest in the natural history of the disease for each individual patient. One patient with stable disease at the end of rIL-2 induction is alive and well, with a stable number of blasts in the bone marrow, 18 months later. These 7 patients continue maintenance treatment with subcutaneous rIL-2. Close clinical and laboratory monitoring reveal that side effects are acceptable and no toxic deaths have been recorded. This update confirms the feasibility and antileukemic activity of high dose rIL-2 in advanced AML patients with limited disease, and suggests a potential clinical role of prolonged rIL-2 maintenance treatment.
- Subjects :
- Acute Disease
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Child
Disease-Free Survival
Feasibility Studies
Female
Fever chemically induced
Follow-Up Studies
Gastrointestinal Diseases chemically induced
Hematologic Diseases chemically induced
Humans
Immunologic Factors administration & dosage
Immunologic Factors adverse effects
Infusions, Intravenous
Injections, Subcutaneous
Interleukin-2 administration & dosage
Interleukin-2 adverse effects
Leukemia, Myeloid drug therapy
Leukemia, Myeloid mortality
Male
Middle Aged
Oliguria chemically induced
Recombinant Proteins therapeutic use
Salvage Therapy
Treatment Outcome
Immunologic Factors therapeutic use
Interleukin-2 therapeutic use
Leukemia, Myeloid therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1042-8194
- Volume :
- 21
- Issue :
- 5-6
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 9172807
- Full Text :
- https://doi.org/10.3109/10428199609093440